Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 5Terminated 3Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Gastric Adenocarcinoma 1Erectile Dysfunction 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Tadalafil × Clear all
NCT05709574 2025-10-16

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

University of Arizona

Phase 2 Recruiting
10 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT05558007 2024-10-22

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Biozeus Biopharmaceutical S.A.

Phase 2 Recruiting
72 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡